Fundz

Evaris Pharma to buy Mayne's Australian arm

PRIVATENov 06, 2026

Acquiring Company

Evaris Pharma

Acquired Company

Mayne Pharma Group Limited

PerthBiotechnologyPharmaceuticalBiotechnologyHealth CarePharmaceutical

Description

Mayne Pharma is selling all of its Australian operations, including its Salisbury factory, to Perth-based Evaris Pharma for $55.5 million. The deal is expected to complete in early 2027, after which Mayne Pharma will have no assets in Australia. The Salisbury factory's 240 workers are to remain with the business.

Who to call at Evaris Pharma, and when

When Evaris Pharma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Evaris Pharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Evaris Pharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Evaris Pharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Evaris Pharma

Location

Perth, Western Australia, Australia

About

Evaris Pharma is a Perth-based pharmaceutical company. It is committed to the Salisbury site in South Australia. Its CEO is Steffan Crausaz.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Evaris Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Evaris Pharma's next move

Learn about Strategic plan

Frequently asked

Who acquired Mayne Pharma Group Limited?

Mayne Pharma Group Limited was acquired by Evaris Pharma, based in Perth. The deal was reported on November 6, 2026. Evaris Pharma is a Perth-based pharmaceutical company. It is committed to the Salisbury site in South Australia. Its CEO is Steffan Crausaz. Evaris Pharma is privately held and operates in Biotechnology.

When did Evaris Pharma acquire Mayne Pharma Group Limited?

Evaris Pharma's acquisition of Mayne Pharma Group Limited was reported on November 6, 2026. Mayne Pharma is selling all of its Australian operations, including its Salisbury factory, to Perth-based Evaris Pharma for $55.5 million. The deal is expected to complete in early 2027, after which Mayne Pharma will have no assets in Australia. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Mayne Pharma Group Limited do?

Mayne Pharma Group Limited is a pharmaceutical company based in Australia. It has a proven commercial expertise and is known for its strength in women's health and dermatology. It is privately held, operating in Biotechnology.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.